Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Q4 Revenues Up 12 Percent, Loss Narrows 65 Percent

NEW YORK, Feb. 18 (GenomeWeb News) - Caliper Life Sciences today reported a 12-percent increase in revenues for the fourth quarter while its net loss narrowed 65 percent.


Caliper had total revenues of $24 million for the period ended Dec. 31, 2004, up from $21 million for the same quarter last year.


The company said R&D spending fell to $4.7 million from $7.6 million year over year.


The company's net loss was $7 million, compared to $20 million in the year-ago period. Caliper said it took a $3.6 million non-cash charge in the quarter for closing the second of its three facilities in Mountain View, Calif. The company said it took the charge because of a "low probability of obtaining sublease income" from the facilities.


Caliper said it had around $9.4 million in cash and cash equivalents and $40 million in short-term marketable securities as of Dec. 31, 2004.

Looking ahead, the company said it expects first-quarter revenues to be between $17 million and $19 million, and to reach operating cash-flow breakeven point in the fourth quarter of 2005. Caliper posted $16.9 million in revenue during the first quarter of 2004.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.